Aranscia Acquires Spesana
Electronic Health Systems Pioneer Carla Balch Joins Aranscia's Executive Leadership Team
HOUSTON, May 12, 2025 /PRNewswire/ -- Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced that it has acquired Spesana and its best-in-class suite of patient navigation, clinical collaboration, and oncology clinical decision support utilities. Spesana's Founder and CEO, Carla Balch, a leading pioneer in healthcare and oncology information systems, will serve as Executive Director across all Aranscia software solutions, including oversight of Spesana's continued commercial and technical expansion.
Spesana, founded in 2019, has developed a healthcare platform that increases the velocity, efficiency, and utility of innovative precision medicine programs. The Company's patient navigation, prior authorization, clinical trial collaboration, and diagnostic workflow solutions are in use across over 140 clinical sites, and its blue-chip customer base includes leading payers, multi-site provider and oncology organizations, and diagnostic laboratories. Spesana clients have reported a 60% improvement in the use of appropriate precision medicine diagnostics by eliminating clinical overhead and process ambiguity with Spesana's intelligent platform utilities.
Spesana will join the Aranscia portfolio of companies, each of which shares a synergistic mission of solving the tactical gaps in clinical workflows and democratizing access to the promises of precision care. This portfolio includes 2bPrecise, the award-winning platform for lab-agnostic, EMR-integrated solutions that deliver unparalleled speed-to-value in precision care; YouScript, a widely recognized leader in actionable, real-time personalized medication risk management and pharmacogenomics (PGx) insights; and AccessDx Laboratory, a CLIA-certified, CAP-accredited, and NYCQ molecular diagnostic laboratory with specialist expertise in PGx and other personalized diagnostics.
"We warmly welcome the entire Spesana team and platform to the Aranscia family of companies," said Joe Spinelli, Chief Strategy Officer, Aranscia. "Spesana and Aranscia have a clear and shared mission of developing and implementing best-in-class utilities that improve clinical, financial, and operational workflows for providers and the patients they serve. Carla's experience as a proven operator, builder, and ally to clinical partners makes her a perfect fit to lead Aranscia's software efforts as we assert our unified focus on positively impacting outcomes at the point of care."
Ms. Balch was previously President and CEO of Altos Solutions, which developed the first web-based oncology medical records company (OncoEMR), and was subsequently acquired by Flatiron Health (now part of Roche). Prior to Spesana, Ms. Balch also served as President of Nantcare, an oncology technology and clinical trials company, and as CEO of Inteliquet (acquired by IQVIA), an innovative clinical trial matching solution. Ms. Balch serves on the Healthcare Counsel of the Federal Reserve Bank of St. Louis.
"We built Spesana to unify fragmented healthcare workflows, and joining Aranscia allows us to realize that mission at scale," said Carla Balch, CEO of Spesana. "Our teams share a commitment to modernizing the clinician experience by eliminating technology silos and delivering a seamless, integrated, HIPAA-compliant platform across all specialties and sites of care. Together, and in collaboration with the clinical partners we serve, we will continue to deliver solutions that improve both patient outcomes and provider experiences and help to enable more connected, efficient, and intelligent healthcare."
About Aranscia:
Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit www.aranscia.com
About Spesana:
Spesana has developed a universal healthcare platform to increase the velocity of patient access to the right care through improving clinical, financial, and operational workflows. Founded in 2019 by an experienced team of electronic medical record pioneers, Spesana's framework for purpose driven healthcare interoperability incorporates a provider-centric approach to building solutions for challenges such as patient navigation, referral management, prior authorization, lab routing, and multi-site clinical collaboration. For more information, please visit https://www.spesana.com
Contact:
Karina Stabile
(516) 317-5835
View original content to download multimedia:https://www.prnewswire.com/news-releases/aranscia-acquires-spesana-302452431.html
SOURCE Aranscia